METHOTREXATE SUBCUTANEOUS SOLUTION

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Aktiivinen ainesosa:

METHOTREXATE (METHOTREXATE SODIUM)

Saatavilla:

ACCORD HEALTHCARE INC

ATC-koodi:

L04AX03

INN (Kansainvälinen yleisnimi):

METHOTREXATE

Annos:

10MG

Lääkemuoto:

SOLUTION

Koostumus:

METHOTREXATE (METHOTREXATE SODIUM) 10MG

Antoreitti:

SUBCUTANEOUS

Kpl paketissa:

100

Prescription tyyppi:

Prescription

Terapeuttinen alue:

ANTINEOPLASTIC AGENTS

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0107545005; AHFS:

Valtuutuksen tilan:

APPROVED

Valtuutus päivämäärä:

2019-08-07

Valmisteyhteenveto

_METHOTREXATE SUBCUTANEOUS (Methotrexate Injection BP) _
_Page 1 of 45 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
METHOTREXATE SUBCUTANEOUS
Methotrexate Injection
Solution, 7.5 mg / 0.15 mL (50 mg / mL) methotrexate (as methotrexate
sodium), single-
use pre-filled syringe for subcutaneous injection
Solution, 10 mg / 0.2 mL (50 mg / mL) methotrexate (as methotrexate
sodium), single-
use pre-filled syringe for subcutaneous injection
Solution, 12.5 mg / 0.25 mL (50 mg / mL) methotrexate (as methotrexate
sodium), single-
use pre-filled syringe for subcutaneous injection
Solution, 15 mg / 0.3 mL (50 mg / mL) methotrexate (as methotrexate
sodium), single-
use pre-filled syringe for subcutaneous injection
Solution, 17.5 mg / 0.35 mL (50 mg / mL) methotrexate (as methotrexate
sodium), single-
use pre-filled syringe for subcutaneous injection
Solution, 20 mg / 0.4 mL (50 mg / mL) methotrexate (as methotrexate
sodium), single-
use pre-filled syringe for subcutaneous injection
Solution, 22.5 mg / 0.45 mL (50 mg / mL) methotrexate (as methotrexate
sodium), single-
use pre-filled syringe for subcutaneous injection
Solution, 25 mg / 0.5 mL (50 mg / mL) methotrexate (as methotrexate
sodium), single-
use pre-filled syringe for subcutaneous injection
BP
Immunosuppressant
Accord Healthcare Inc.
3535 boul. St-Charles, Suite 704
Kirkland, QC, H9H 5B9
Canada
Submission Control Number: 263562
Date of Initial Approval:
August 2, 2019
Date of Revision:
October 3, 2022
_METHOTREXATE SUBCUTANEOUS (Methotrexate Injection BP) _
_Page 2 of 45 _
RECENT MAJOR LABEL CHANGES
7. Warnings and Precautions
10/2022
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
................................................................... 4
1
INDICATIONS
..........................................................................................................................
4
1.1
Pediatrics
...........................................................................................................................
4
1.2
Geriatrics